Barinthus Biotherapeutics (BRNS) Projected to Post Quarterly Earnings on Monday

by · The Markets Daily

Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect Barinthus Biotherapeutics to post earnings of ($0.34) per share for the quarter.

Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The company had revenue of $14.97 million for the quarter. On average, analysts expect Barinthus Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Barinthus Biotherapeutics Price Performance

Shares of BRNS stock opened at $0.91 on Monday. Barinthus Biotherapeutics has a 1-year low of $0.64 and a 1-year high of $2.45. The firm has a market cap of $36.79 million, a PE ratio of -0.61 and a beta of -0.77. The company has a 50-day moving average of $0.89 and a two-hundred day moving average of $1.03.

Analyst Upgrades and Downgrades

BRNS has been the topic of a number of research analyst reports. Alliance Global Partners reissued a “buy” rating on shares of Barinthus Biotherapeutics in a research report on Monday, March 24th. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Barinthus Biotherapeutics in a research note on Friday, March 21st.

Read Our Latest Stock Analysis on BRNS

Barinthus Biotherapeutics Company Profile

(Get Free Report)

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.

Featured Articles